Trial reportAntimicrobial agents and chemotherapy1997
Survival of anti-Clostridium difficile bovine immunoglobulin concentrate in the human gastrointestinal tract.
Trial report in Antimicrobial agents and chemotherapy, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 104 citations in OpenAlex.
- Nutritional Impact of Dietary Plasma Proteins in Animals Undergoing Experimental Challenge and Implications for Patients with Inflammatory Bowel Disorders: A Meta-analysis.Advances in nutrition (Bethesda, Md.) · 2015Pooled it
- Trial
- Mucosal Vaccination Strategies againstVaccines · 2023Review
- Immunoregulatory Effects of Porcine Plasma Protein Concentrates on Rat Intestinal Epithelial Cells and Splenocytes.Animals : an open access journal from MDPI · 2021Article
- Structural features of bovine colostral immunoglobulin that confer proteolytic stability in a simulated intestinal fluid.The Journal of biological chemistry · 2020Article
- Quantitative Analysis of Antibody Survival across the Infant Digestive Tract Using Mass Spectrometry with Parallel Reaction Monitoring.Foods (Basel, Switzerland) · 2020Article
- Article
- Effects of Bovine Immunoglobulins on Immune Function, Allergy, and Infection.Frontiers in nutrition · 2018Review
- Article
- Application of Antibody-Mediated Therapy for Treatment and Prevention ofFrontiers in microbiology · 2018Review
- TargetingFrontiers in microbiology · 2018Review
- Bovine antibodies targeting primary and recurrent Clostridium difficile disease are a potent antibiotic alternative.Scientific reports · 2017Article
- Breakthroughs in the treatment and prevention of Clostridium difficile infection.Nature reviews. Gastroenterology & hepatology · 2016Review
- Neutralization of Clostridium difficile Toxin B Mediated by Engineered Lactobacilli That Produce Single-Domain Antibodies.Infection and immunity · 2016Article
- Absorption and safety of serum-derived bovine immunoglobulin/protein isolate in healthy adults.Clinical and experimental gastroenterology · 2016Article
- Hyperimmune bovine colostrum as a novel therapy to combat Clostridium difficile infection.The Journal of infectious diseases · 2015Article
- Survival and digestibility of orally-administered immunoglobulin preparations containing IgG through the gastrointestinal tract in humans.Nutrition journal · 2015Review
- Immune-based treatment and prevention of Clostridium difficile infection.Human vaccines & immunotherapeutics · 2014Review
- Perspectives on immunoglobulins in colostrum and milk.Nutrients · 2011Review
- Neutralization of Clostridium difficile toxin A with single-domain antibodies targeting the cell receptor binding domain.The Journal of biological chemistry · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
To be therapeutically active, oral hyperimmune bovine immunoglobulin concentrate (BIC) must survive its passage through the intestinal tract. This led us to study the gastrointestinal stability of orally administered BIC directed against Clostridium difficile toxins (BIC-C. difficile). BIC-C. difficile was stable at neutral pH in vitro but was degraded at low pH, particularly in the presence of pepsin. Healthy volunteers (n = 6) took BIC-C. difficile (45 or 8 g) as a single oral dose. Total bovine immunoglobulin G (IgG) and specific anti-C. difficile IgG were measured in the stool. BIC was given under the following conditions: in the fasting state, in the fed state, with antacid, during omeprazole therapy, or in enteric capsules (released at pH > 6). The mean fecal bovine IgG content of 3-day stool collections was similar in the fasting (536 mg; 3.8% of the ingested dose of BIC), fed (221 mg; 1.6%), and antacid (381 mg; 2.7%) groups. Omeprazole therapy was associated with increased fecal bovine IgG levels (1253 mg; 8.8%), but this difference did not reach statistical significance (P = 0.07). Administration of 8 g of BIC-C. difficile in enteric capsules resulted in substantially higher fecal bovine IgG levels (1,124 mg; 32.7% of the oral dose) than those obtained after administration of nonencapsulated BIC (22 MG; 0.6%; P = 0.004). An inverse relationship was noted between intestinal transit time and fecal bovine IgG content (R = 0.83; P = 0.04 [data from omeprazole group]). Filtrates of stool samples collected after oral administration of BIC-C. difficile neutralized the cytotoxicity of C. difficile toxins A and B, whereas control stool filtrates did not. Bovine colostral IgG undergoes partial degradation in the intestinal tract. Exposure to acidic gastric secretions and prolonged colonic transit may both contribute to IgG degradation. Nonetheless, humans taking BIC-C. difficile orally have neutralizing antitoxin activity in their stool.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.